FDA approves AstraZeneca’s drug for rare form of blood cancer

FDA approves AstraZeneca’s drug for rare form of blood cancer

The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc’s treatment for hairy cell leukemia, a slow-growing type of blood cancer.

The treatment, marketed as Lumoxiti, was approved for treating a stubborn form of the disease or a relapse in patients who have received at least two prior therapies, the FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm said.

Lumoxiti includes a boxed warning advising health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels.

The warning also notes the risk of hemolytic uremic syndrome, a condition caused by the abnormal destruction of red blood cells.

Hairy cell leukemia is a rare form of blood cancer in which the bone marrow makes too many B cells, a type of white blood cell that fights infection.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D’Silva)


Published at Thu, 13 Sep 2018 11:39:30 -0700

You might also like